A Randomized, Open-label, Crossover Trial of the Effect of High-dose Daily HSV-2 Suppressive Therapy on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Aciclovir (Primary) ; Valaciclovir (Primary)
- Indications Herpes simplex virus type 2 infections; HIV-1 infections
- Focus Therapeutic Use
- Acronyms ACV-VAL
Most Recent Events
- 08 Apr 2014 Biomarkers information updated
- 20 Jul 2011 Status changed from active, no longer recruiting to completed.
- 02 Feb 2011 Planned end date changed from 1 Feb 2011 to 1 Dec 2010 as reported by ClinicalTrials.gov record.